ICU Medical Inc. research snapshot
ICUI AI stock analysis reads ICU Medical as a specialized medical technology company focused on infusion systems, infusion consumables, and high-value vital care products after the May 2025 divestiture of its IV Solutions business into an Otsuka joint venture. The analysis is not a guaranteed price prediction. At the August 4, 2026 cutoff, the latest verified price used here was about $172.47, market capitalization was about $4.31 billion, and the stock had just reached its 52-week high near $176.27. The main question is whether the improving margins, the Otsuka IV solutions expansion, the upcoming August 6 Q2 2026 report, and a multiyear pump replacement cycle can justify the valuation against FDA recalls of the Plum Duo and Plum Solo infusion pumps and roughly $1.28 billion of debt. This is informational research and not investment advice.
Current price
$172.47
Market cap
$4.31 billion
AI score
63 / 100
Rating
Improved niche medical technology operator with analyst support but a fresh pump recall and a heavy debt load
Trend status
Strong uptrend pressing the 52-week high near $176, well above the 50-day and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ICU Medical provides infusion systems, infusion consumables, and critical care products that hospitals depend on daily. Recurring consumable revenue provides stability, and Q1 2026 gross margin improved to 39%, but reported revenue was down because of the IV Solutions divestiture. | Medium |
| Moat | FDA-approved designs, hospital relationships, installed infusion pump fleets that create switching costs, and sterile manufacturing scale create a moderate moat. B. Braun, Becton Dickinson, Baxter, and Fresenius continue to compete across infusion categories. | Medium |
| Management | CEO Vivek Jain has focused on margin improvement, debt reduction, and the Otsuka IV solutions joint venture since 2020. Q1 2026 adjusted EPS of $1.97 beat consensus and gross margin rose to 39%, but the long track record is still being built. | Medium |
| Financial trend | TTM revenue was about $2.16 billion with GAAP net income of roughly $46 million and EPS of $1.85. Q1 2026 GAAP net income was $30.1 million, adjusted EPS was $1.97, and adjusted EBITDA was $98.7 million, with guidance of $7.75 to $8.45 adjusted EPS for fiscal 2026. | Medium-high |
| Valuation | The stock traded near 91x TTM GAAP earnings, about 52x TTM free cash flow, and roughly 21x the fiscal 2026 adjusted EPS consensus of $8.17 at the cutoff. The adjusted forward multiple is more reasonable, but the GAAP multiple and EV/EBITDA near 22x leave limited margin of safety. | Medium |
| Technical trend | ICUI reached a 52-week high near $176.27, well above the 50-day moving average of about $147 and the 200-day moving average of about $139, with RSI near 67. The trend is strong but approaching overbought territory. | Medium-high |
| Risk level | Key risks include FDA recalls of the Plum Duo and Plum Solo pumps, roughly $1.28 billion of debt with net debt of about $1 billion, customer and distributor concentration, competition from larger medtech players, tariffs, and the risk that margin improvement stalls. | Medium |
| AI confidence | Medium-high confidence for the business map, Q1 2026 filings, market cap math, analyst consensus, and major risk categories. Lower confidence for the durability of margin expansion, recall resolution timing, and the pace of the pump replacement cycle. | Medium-high data confidence |
| Investment certainty | Medium-low certainty. ICU Medical has an essential product portfolio and improving margins, but the stock price near the 52-week high already embeds high expectations, and recall and debt risks add uncertainty. | Medium-low |
ICUI AI stock forecast
The ICUI AI stock forecast uses scenario ranges around the $172.47 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires strong Q2 2026 results on August 6, a durable pump replacement cycle, controlled recall costs, and continued margin improvement. The base case assumes adjusted EPS near the fiscal 2026 guidance midpoint with the stock consolidating near analyst targets. The bearish case assumes recall escalation, tariff or integration cost pressure, or a Q2 miss that compresses the adjusted forward multiple.
$195 to $230
More likely if Q2 2026 results exceed expectations, the Plum recall costs stay contained, the Otsuka IV solutions expansion adds capacity without margin dilution, and the pump replacement cycle drives revenue acceleration that supports a higher adjusted forward multiple.
$160 to $195
More likely if fiscal 2026 adjusted EPS lands near the $7.75 to $8.45 guidance and roughly $8.17 consensus, margins hold near Q1 2026 levels, and the stock trades in a range reflecting steady but unexciting improvement near analyst price targets.
$115 to $145
More likely if FDA recall scrutiny escalates into revenue disruption or higher remediation costs, competitive pressure from larger medtech players intensifies, hospital capital spending slows, or tariff and integration costs weigh on margins and revenue.
ICUI AI technical analysis
ICUI AI technical analysis starts from the $172.47 August 3, 2026 price used for this August 4 static page. Public technical sources showed the stock at its 52-week high near $176.27, well above the 50-day and 200-day moving averages, with RSI near 67. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $172.47 | Latest verified price as of the August 3, 2026 data used for this page. The stock hit a 52-week high of $176.27 the same day. |
| Near support | $160 to $165 | The area around the recent breakout zone and prior consolidation. A hold above this zone supports the continuation of the uptrend. |
| Secondary support | $147 to $150 | The 50-day moving average area near $147. A deeper pullback would likely find buyers in this zone if the near support is broken. |
| Near resistance | $176 to $180 | The 52-week high area near $176.27. A breakout above this zone with volume would confirm the trend extension toward the high end of analyst targets. |
| 52-week range | $107.00 to $176.27 | The full 52-week range. The stock was at the top of this range at the cutoff after a roughly 34% gain over the trailing 52 weeks. |
| Momentum | RSI about 67, bullish but elevated | Momentum is strong and bullish, but RSI near 67 is approaching overbought levels, which increases the chance of short-term consolidation. |
| Volume | Average volume about 278,000 shares | The 20-day average volume was roughly 278,000. Breakout attempts or breakdowns should ideally be confirmed by above-average volume. |
| Volatility | Beta 0.76 | Low-to-moderate beta relative to the market. Position sizing should account for normal daily movement around the cutoff price. |
| Invalidation | Close below $160, then $147 | A close below the $160 area would weaken the near-term technical setup. A break below the 50-day moving average near $147 would challenge the broader uptrend. |
ICUI AI trading strategy
The ICUI AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Look for ICUI to hold above the $160 to $165 support area and break above the $176 to $180 52-week high zone on expanding volume before treating momentum as confirmed.
A failed breakout or daily close below the $160 area should reduce confidence in the continuation setup. Watch the August 6 Q2 2026 earnings reaction as a catalyst.
If ICUI pulls back toward the $147 to $150 moving average zone without a fundamental thesis break, compare price stabilization with recall updates, Otsuka JV developments, and margin trajectory.
Do not average down solely because the stock is off recent highs. Define maximum loss and review the quarterly earnings trajectory, recall status, and debt profile first.
Track Q2 2026 results on August 6, full-year 2026 adjusted EPS and EBITDA versus the $7.75 to $8.45 guidance, gross margin trends, debt-to-EBITDA ratio, Plum recall remediation costs, and Otsuka JV capacity expansion.
Lower the rating if the recall escalates into revenue disruption, revenue growth stays negative while the stock holds a premium multiple, or debt reduction stalls.
Investment research summary
ICU Medical sells infusion pumps, infusion consumables, and vital care products that hospitals use daily to deliver fluids, medications, and blood products to patients. After the May 2025 IV Solutions divestiture into an Otsuka joint venture, the company is a more focused infusion therapy pure play.
The moat comes from FDA-cleared product designs, hospital procurement relationships, installed infusion pump fleets that create switching costs, and sterile manufacturing know-how. Competitive pressure from B. Braun, Becton Dickinson, Baxter, and Fresenius limits pricing power.
The thesis can fail if FDA recall scrutiny of the Plum Duo and Plum Solo pumps expands into revenue disruption, large competitors use scale to undercut pricing, the Otsuka JV does not deliver expected synergies, or the debt burden from past acquisitions constrains strategic flexibility.
CEO Vivek Jain has refocused the company on margin improvement, debt reduction, and the Otsuka IV solutions joint venture. Q1 2026 adjusted EPS of $1.97 beat consensus and gross margin improved to 39%, but building a sustained track record takes time.
Demand for IV therapy, infusion systems, and safe drug delivery is structurally supported by aging populations and increasing chronic disease prevalence. A multiyear pump replacement cycle and the Otsuka IV solutions capacity expansion are positive drivers, but competitive intensity remains high.
At roughly 91x TTM GAAP earnings, about 52x TTM free cash flow, and about 21x fiscal 2026 adjusted EPS, the stock price embeds high expectations for margin improvement and earnings growth. A margin of safety would require either lower entry price or stronger evidence of sustained operating leverage.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ICUI price | $172.47 on August 3, 2026, 52-week high $176.27 | StockAnalysis.com and Google Finance | August 4, 2026 |
| Market capitalization | $4.31 billion, verified as $172.47 x 24,990,000 shares | financial_rigor.py market cap verification and StockAnalysis.com | August 4, 2026 |
| Q1 2026 revenue | $530.2 million, down 12% year over year on the IV Solutions divestiture, organic growth up 1% | ICU Medical Q1 2026 press release, May 7, 2026 | August 4, 2026 |
| Q1 2026 adjusted EPS | $1.97, versus $1.72 in Q1 2025, beating consensus | ICU Medical Q1 2026 press release and analyst reports | August 4, 2026 |
| Q1 2026 adjusted EBITDA | $98.7 million, versus $99.4 million in Q1 2025 | ICU Medical Q1 2026 press release | August 4, 2026 |
| Q1 2026 GAAP net income | $30.1 million, or $1.20 per diluted share | ICU Medical Q1 2026 press release | August 4, 2026 |
| TTM revenue | About $2.16 billion | StockAnalysis.com financials (S&P Global Market Intelligence) | August 4, 2026 |
| TTM net income and EPS | About $46 million GAAP net income and $1.85 EPS | StockAnalysis.com statistics (S&P Global Market Intelligence) | August 4, 2026 |
| Shares outstanding | Approximately 24.99 million | StockAnalysis.com and Google Finance | August 4, 2026 |
| Debt and cash | Total debt about $1.28 billion, cash about $288 million, net debt about $1.0 billion | ICU Medical Q1 2026 balance sheet and StockAnalysis.com | August 4, 2026 |
| Valuation math | 90.98x TTM PE, 52.16x TTM P/FCF, 67.65x forward PE (GAAP), about 21x fiscal 2026 adjusted EPS, 2.00x PS, EV/EBITDA 21.91x | StockAnalysis.com statistics and financial_rigor.py valuation verification | August 4, 2026 |
| Analyst consensus | Buy, average price target $176.63, range $163 to $200 from 8 analysts | StockAnalysis.com forecast (S&P Global Market Intelligence and TipRanks) | August 4, 2026 |
| 52-week range | $107.00 to $176.27 | StockAnalysis.com and Google Finance | August 4, 2026 |
| Plum pump recall | Voluntary Class II recalls of Plum Duo and Plum Solo infusion pumps cited by US regulators for a software issue affecting displayed dosing volumes | US FDA enforcement reports via Simply Wall St, August 2, 2026 | August 4, 2026 |
This ICUI AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. ICU Medical faces FDA recall, leverage, and competitive risks that are not fully captured by any single model.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
